Geoffrey Porges
Stock Analyst at SVB Leerink
(1.34)
# 3,576
Out of 5,050 analysts
122
Total ratings
42.86%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.43 | +129.23% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $19.31 | +417.87% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $657.53 | +29.27% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $68.24 | -29.66% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $320.20 | -32.54% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $219.16 | -38.40% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $20.62 | -46.65% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $118.84 | -36.89% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $49.66 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $14.75 | -32.20% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $11.03 | +6,699.64% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $409.47 | -57.26% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $31.20 | +169.23% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $46.63 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $7.86 | +676.08% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $155.51 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.43
Upside: +129.23%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $19.31
Upside: +417.87%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $657.53
Upside: +29.27%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $68.24
Upside: -29.66%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $320.20
Upside: -32.54%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $219.16
Upside: -38.40%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $20.62
Upside: -46.65%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $118.84
Upside: -36.89%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $49.66
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $14.75
Upside: -32.20%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $11.03
Upside: +6,699.64%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $409.47
Upside: -57.26%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $31.20
Upside: +169.23%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $46.63
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $7.86
Upside: +676.08%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $155.51
Upside: -